semaglutide loss of exclusivity The $300B Erosion Problem: How Drug Market Share Actually Dies After Patent Expiry Your Questions Answered: Off-patent Semaglutide

Drugs are not inherently bad but this comes at a high cost with dubious efficacy: - $1,500-3,000 in annual out-of-pocket costs per person - 1.5M ER visits yearly from adverse drug interactions - Higher risks of kidney, liver and other bodily injuries For #healthcare founders and operators, theres an important opportunity to improve lives while bringing down costs for everyone

Pricing Transparency All-inclusive pricing is shown upfront and includes medication, supplies, medical consultations, and ongoing support

Quality of life enhancements extend to increased physical capability, improved sleep, and enhanced self-confidence across Hawaiian communities

Finally, the model results support the conclusions of Mosharov et al

W.YousifN